Press releases
- Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter
- Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD
- Dexcom Announces Upcoming Conference Presentation
- Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results
- Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People
- Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time
- Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland
- A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2
- Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook
More ▼
Key statistics
On Thursday, Dexcom Inc (DC4:FRA) closed at 128.52, -2.55% below its 52-week high of 131.88, set on Mar 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 128.52 |
---|---|
High | 128.52 |
Low | 128.52 |
Bid | -- |
Offer | -- |
Previous close | 130.42 |
Average volume | 860.11 |
---|---|
Shares outstanding | 385.52m |
Free float | 383.80m |
P/E (TTM) | 108.80 |
Market cap | 53.77bn USD |
EPS (TTM) | 1.28 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:20 BST.
More ▼